A Phase 4 Study of Nivolumab in Combination With Ipilimumab in Patients With Previously Untreated Advanced Renal Cell Carcinoma and Intermediate-or Poor-risk Factors Conducted in India
Latest Information Update: 16 Feb 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Acronyms CheckMate 7C9
- Sponsors Bristol-Myers Squibb
- 12 Feb 2024 Status changed from active, no longer recruiting to completed.
- 18 Aug 2023 Status changed from recruiting to active, no longer recruiting.
- 25 Apr 2022 Planned primary completion date changed from 28 Dec 2023 to 29 Dec 2023.